T7947
（R）-托莫西汀 盐酸盐
solid
别名:
盐酸托莫西汀 盐酸盐, （R）-N-甲基-γ-（2-甲基苯氧基）苯丙胺 盐酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H21NO · HCl
化学文摘社编号:
分子量:
291.82
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
（R）-托莫西汀 盐酸盐, solid
InChI key
LUCXVPAZUDVVBT-UNTBIKODSA-N
SMILES string
CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl
InChI
1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
form
solid
originator
Eli Lilly
storage temp.
2-8°C
Quality Level
Gene Information
human ... SLC6A2(6530)
正在寻找类似产品? 访问 产品对比指南
相关类别
Biochem/physiol Actions
去甲肾上腺素摄取阻滞剂。
(R)-Tomoxetine hydrochloride is an efficient inhibitor of presynaptic norepinephrine transporters. It also positively regulates the release of acetylcholine in the prefrontal cortex (PFC). (R)-Tomoxetine hydrochloride binds to the serotonin (5-HT) transporter. It is involved in blocking the cortical N-methyl-D-aspartate (NMDA) receptors.. (R)-Tomoxetine hydrochloride exhibits therapeutic effects against attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).
Application
(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:
- to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice
- to study its effects on set shifting in rats
- to study its effects on rat brain as a result of its long-term use
Features and Benefits
This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Grazia Dell'Agnello et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 19(11), 822-834 (2009-09-01)
The primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support. This was
Chi-Yung Shang et al.
Journal of child and adolescent psychopharmacology, 22(5), 353-363 (2012-10-23)
Atomoxetine is efficacious in reducing symptoms of attention- deficit/hyperactivity disorder (ADHD), but its effect on visual memory and attention needs more investigation. This study aimed to assess the effect of atomoxetine on visual memory, attention, and school function in boys
Romano Arcieri et al.
Journal of child and adolescent psychopharmacology, 22(6), 423-431 (2013-01-31)
The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. This study was an open, prospective, observational study of youth with
Christina A Wilson et al.
Pharmacology, biochemistry, and behavior, 104, 47-61 (2013-01-05)
Rats repeatedly exposed to variable prenatal stress (PNS) exhibit behavioral signs that are similar to those manifested in several neuropsychiatric disorders such as deficits in attention and inhibitory control, and impairments in memory-related task performance. The purpose of the study
Himanshu P Upadhyaya et al.
Psychopharmacology, 226(2), 189-200 (2013-02-12)
Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持